Novo Nordisk revised its sales growth forecast downward for 2025 due to continued competition from compounded GLP-1 drugs and market challenges affecting its obesity medications, Wegovy and Ozempic. The Danish pharma reported slower U.S. sales and announced the appointment of Mike Doustdar as new CEO, who will lead the company amid these headwinds. This transition coincides with a reorganization of R&D under a new chief scientist aiming to bolster innovation despite weakening near-term growth prospects.